Jefferies reiterated a Buy rating on Cubist Pharmaceuticals (NASDAQ: CBST) and raised its price target to $55.00 (from $52.00).

This article: 124 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE